Slobodan Stanisic, MD
Hematology & Oncology · Cincinnati, OHNPI 1740276823
Payments from drug & device makers
Across 116 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$214
- Takeda Pharmaceuticals U.S.A., Inc.$203
- E.r. Squibb & Sons, L.L.C.$173
- Genentech USA, Inc.$144
- Bayer$134
- Johnson & Johnson$121
- plus $1K from 28 others
What the payments were for
- Food & beverage$1,62780%
- Education$40120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $203 |
| E.r. Squibb & Sons, L.L.C. | 12 | $173 |
| Genentech USA, Inc. | 5 | $144 |
| Bayer | 10 | $134 |
| Johnson & Johnson(2 entities) | 12 | $121 |
| Sanofi | 5 | $108 |
| Regeneron Healthcare Solutions, Inc. | 6 | $104 |
| Novartis | 5 | $82 |
| Merck | 5 | $70 |
| Blueprint Medicines Corporation | 1 | $55 |
| Tempus AI, Inc | 2 | $54 |
| Exelixis Inc. | 1 | $46 |
| Tesaro, Inc. | 2 | $45 |
| AbbVie | 3 | $45 |
| AstraZeneca | 3 | $42 |
| Lilly USA, LLC | 3 | $42 |
| Pfizer | 3 | $40 |
| Dendreon Pharmaceuticals LLC | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Amgen | 2 | $30 |
| Clovis Oncology, Inc. | 2 | $24 |
| Rigel Pharmaceuticals, Inc. | 2 | $23 |
| Abbott | 1 | $20 |
| GSK | 1 | $18 |
| Incyte Corporation | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Verastem, Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$2,028 in reported general payments places this provider in the 35th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 22 | $448,529 |
| CalquenceAcalabrutinib Maleate | 18 | $266,491 |
| JakafiRuxolitinib Phosphate | 13 | $259,856 |
| ImbruvicaIbrutinib | 16 | $233,205 |
| VerzenioAbemaciclib | 14 | $221,338 |
| Lenalidomide | 13 | $171,713 |
| XtandiEnzalutamide | 11 | $149,459 |
| GleevecImatinib Mesylate | 12 | $122,077 |
| EliquisApixaban | 96 | $67,470 |
| XareltoRivaroxaban | 27 | $31,830 |
| Potassium Chloride | 56 | $2,578 |
| Anastrozole | 116 | $1,871 |
| Oxycodone Hcl | 43 | $1,172 |
| Gabapentin | 39 | $862 |
| Hydroxyurea | 43 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $13 | $448,52922 claims |
| AstraZenecaCalquence | $42 | $266,49118 claims |
| Incyte CorporationJakafi | $16 | $259,85613 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $233,20516 claims |
| Lilly USA, LLCVerzenio | $42 | $221,33814 claims |
| Astellas Pharma US IncXtandi | $214 | $149,45911 claims |
| NovartisGleevec | $82 | $122,07712 claims |
| PfizerEliquis | $40 | $67,47096 claims |
| Johnson & JohnsonXarelto | $121 | $31,83027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- David WaterhouseCincinnati$5.7M
- Patrick WardCincinnati$3.8M
- James EssellCincinnati$3.7M
- Edward FaberCincinnati$2.3M
- Omar AlkharabshehCincinnati$1.2M
- Alexander StarodubCincinnati$1.1M
- Mark JohnsCincinnati$999K
- Jason JonesCincinnati$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.